TRCT
AGN

Tower Research Capital (TRC)’s Allergan Inc AGN Stock Holding History

Tower Research Capital (TRC)’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-62
Closed -$13K – 5642
2014
Q4 		$13K Sell
62
-4,844
-99% -$963K ﹤0.01% 1962
2014
Q3 		$875K Buy
4,906
+4,801
+4,572% +$797K 0.1% 182
2014
Q2 		$18K Buy
105
+86
+453% +$13.4K ﹤0.01% 1927
2014
Q1 		$2K Sell
19
-800
-98% -$97.4K ﹤0.01% 4084
2013
Q4 		$91K Sell
819
-6,351
-89% -$607K 0.02% 925
2013
Q3 		$648K Buy
7,170
+6,719
+1,490% +$603K 0.07% 257
2013
Q2 		$38K Buy
+451
New +$46.8K ﹤0.01% 1158

Other funds holding AGN

California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
AIM
Advantage Investment Management Cedar Rapids, Iowa $128M AUM 0.94% 1-Year Est. Return

Tower Research Capital (TRC)'s AGN Position: Q1 2015 in Review

Tower Research Capital (TRC) sold out of Allergan Inc (AGN) in Q1 2015, closing a stake of 62 shares — an estimated $13K sold.

Tower Research Capital (TRC) first reported a position in AGN in Q2 2013 and held it in 7 quarters. The position peaked at $875K in Q3 2014. 5 funds tracked by Wall St. Rank hold AGN as of Q1 2015.

  • Tower Research Capital (TRC) reported no remaining Allergan Inc position as of Q1 2015 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 62 Allergan Inc shares in Q1 2015, an estimated $13K.
  • Tower Research Capital (TRC) first reported a position in Allergan Inc in Q2 2013 and held it in 7 quarters.
  • Tower Research Capital (TRC)'s Allergan Inc position peaked at $875K in Q3 2014.
  • 5 funds tracked by Wall St. Rank held Allergan Inc as of Q1 2015.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2015, filed 12 May 2015.